Repurposing auranofin in nonalcoholic fatty liver disease still requires further evidence.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and molecular hepatology"
DOI: 10.3350/cmh.2022.0326
Abstract: and the of nuclear factor kappa B (NF-κB) and inhibitor of NF-κB alpha (IκBα) in LX-2 cells; in HepG2 auranofin erythroid 2-related factor 2 (NRF2) significantly and was required for auranofin to exhibit insulin sensitizing… read more here.
Keywords: nonalcoholic fatty; fatty liver; auranofin nonalcoholic; disease still ... See more keywords